Author(s):
Rehan Haider, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed, Sambreen Zameer
Email(s):
rehan_haider64@yahoo.com
DOI:
10.52711/2231-5659.2025.00030 
Address:
Rehan Haider1, Asghar Mehdi2, Geetha Kumari Das3, Zameer Ahmed4, Sambreen Zameer5
1Head of Marketing and Sales, Riggs Pharmaceuticals, Department of Pharmacy, University of Karachi, Pakistan.
2Head, Department of Pharmacology, Fazaia Ruth Pfau Medical College Air college Karachi, Pakistan.
3GD Pharmaceutical Inc, OPJS University, Rajasthan, India.
4Assistant Professor, Dow University of Health Sciences, Karachi, Pakistan.
5Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
Drug manufacturing plays a pivotal role in all-encompassing healthcare, particularly in Organization of Islamic Cooperation (OIC) appendage nations. This paper delves into the dynamics of drug results, consumption, and work within this diverse group of countries and their governments. Production: OIC nations exhibit a wide range of drug production volumes, varying from advanced production abilities to those reliant on imports. Factors doing result include supervisory foundations, technological progress, and expense climates. Consumption: The demand for pharmaceuticals within OIC appendage nations is affected by population headcount, affliction prevalence, healthcare foundation, and socio-business-related factors. Rising incomes and changeful behaviors contribute to increased use, especially for incessant afflictions and innovative analyses. Trade: Intra-OIC drug trade is important, compelled by diverse determinants such as geographic closeness, professional agreements, and financial unification initiatives. Export-familiarized nations influence competitive benefits in terms of result costs and quality principles, while significance-dependent countries, with their governments, inquire about access to essential cures and mechanics know-how. Challenges and Opportunities: Despite progress, drug manufacturing in OIC countries faces challenges containing supervisory harmonization, protected property created by original thought rights, and an approach to financing. However, events thrive, including the potential for OIC cooperation, technology transfer, and competency construction to enhance autonomy and meet healthcare needs. Conclusion: Understanding the action of pharmaceutical results, devouring, and supply with merchandise from OIC member nations is essential for policymakers, manufacturing stakeholders, and worldwide institutions to foster tenable incidents, improve approaches to cures, and promote community health in this place's diverse and active domain.
Cite this article:
Rehan Haider, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed, Sambreen Zameer. Pharmaceutical Industry Dynamics: Production, consumption, and trade in OIC Member countries. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(2):191-8. doi: 10.52711/2231-5659.2025.00030
Cite(Electronic):
Rehan Haider, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed, Sambreen Zameer. Pharmaceutical Industry Dynamics: Production, consumption, and trade in OIC Member countries. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(2):191-8. doi: 10.52711/2231-5659.2025.00030 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2025-15-2-15
REFERENCES:
1. World fitness Organization (WHO), The World Medicine State of Affairs 2004.
2. Bate Dr. Roger (2008), Neighborhood Pharmaceutical Production in Developing Countries.
3. Export Promotion Centre of Turkey, Pharmaceutical Industry 2008.
4. IMS Health Market Diagnosis, March 2011
5. House of Commons Health Committee record 2004-2005 consultation, the effect on the Pharmaceutical Industry.
6. European Federation of Pharmaceutical Industries and Associations (EFPIA), medicines for Mankind - Medicines for Growing International Locations, 2007
7. European Federation of Pharmaceutical Industries and Institutions (EFPIA), The Pharmaceutical Industry in Figures 2008.